Brain Monitoring Market Size, Share & Forecast 2033

The Brain Monitoring Market, estimated at USD 4,458.0 Mn in 2026, is expected to exhibit a CAGR of 7.3% and reach USD 7,300.2 Mn by 2033.

The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.

Market Statistics

The global Brain Monitoring Market is estimated to account for USD 4,458.0 Mn in terms of value by the end of 2026.

Drivers

Increase in demand for brain monitoring devices across the globe is expected to propel the growth of the global brain monitoring market during the forecast period. For instance, with the increase in incidence/prevalence of neurodegenerative disorders, the demand for brain monitoring devices is also increasing rapidly. In November 2025, Neurosteer received the Food and Drug Administration (USFDA) approval for its single-channel electroencephalogram (EEG) brain monitoring platform. Neurosteer’s EEG brain monitoring platform uses a single adhesive forehead strip and provides the traditional EEG frequency bands. The device has also received the USFDA approval to include several new brain metrics visual representations.

Opportunities

Increase in incidence/prevalence of neurological disorders and growing geriatric population across the world is expected to offer significant growth opportunities for players in the brain monitoring market. For instance, brain monitoring devices are used to evaluate several types of neurological disorders, such as Parkinson’s disease. According to the World Health Organization (WHO), the prevalence of Parkinson’s disease (PD) has doubled in the past 25 years. Global estimates in 2025 showed over 8.5 million individuals with PD. Moreover, according to the Parkinson’s Foundation, around one million people in the U.S. are living with Parkinson's disease (PD), and this number is expected to reach 1.2 million by 2032.

Restraints

Stringent regulatory framework for device approval and lack of skilled personnel to handle brain monitoring devices are major factors expected to hamper the growth of the global brain monitoring market. For instance, the U.S. Food & Drug Administration (FDA) classify medical devices based on the level of risk, such as Class I or low risk, Class II or moderate risk and Class III, or high risk. Moreover, lack of highly skilled or trained personnel is one of the significant challenges faced by the market, which hampers the growth of the market in developing and under-developed countries. Thus, there is an increase in demand for highly skilled or trained personnel worldwide.

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/brain-monitoring-market-165

Key Takeaways

The global brain monitoring market was valued at USD 4,458.0 Mn in 2026 and is forecast to reach a value of USD 7,300.2 Mn by 2033 at a CAGR of 7.3% between 2026 and 2033.

Market Trends

One of the key trends expected to propel the growth of the global brain monitoring market is the increase in therapeutic applications of brain monitoring.With the rise in therapeutic applications of brain monitoring devices, the demand for non-invasive and minimally invasive devices is also increasing with a rapid pace. For instance, nowadays, wireless headsets allow readings to be done in a completely non-invasive way and in some cases, assess the patients from the comfort of their homes. Moreover, the use of wearable brain sensors help differentiate cognitive states in several neurodegenerative conditions. This trend is expected to continue over the forecast period, driving the growth of the global brain monitoring market.
Portable and Gel-Free EEG Systems Are Expanding Beyond Hospitals

Brain monitoring is shifting from conventional EEG laboratories toward portable, fast-setup systems for physician offices, outpatient clinics, and home-based testing. In April 2026, Zeto received FDA 510(k) clearance for New Wave, an outpatient EEG system featuring 21 soft-tip, gel-free electrodes, synchronized video and audio, and cloud-based remote access. This trend is helping providers reduce setup complexity and dependence on specialized EEG technicians.

In-Ear EEG Is Enabling Long-Duration, Real-World Monitoring

Miniaturized EEG sensors embedded in earbuds are emerging as an alternative to bulky scalp-mounted systems. At CES 2026, Naox Technologies showcased Naox Link, an in-ear EEG platform designed for prolonged monitoring in neurology, epilepsy, sleep, and clinical research. Its underlying NX01 device received an FDA substantial-equivalence decision on November 25, 2025, supporting its commercialization and clinical adoption during 2026.

Human-in-the-Loop AI Is Strengthening EEG Interpretation

Hospitals are increasingly adopting AI to identify seizures and calculate seizure burden, while retaining expert review for clinical confidence. In April 2026, Zeto launched NeuroNotis, which combines continuous AI-enabled seizure analysis with validation by registered EEG technologists. The technical report is available approximately 15 minutes after the first hour of recording, supporting faster decisions in emergency and critical-care environments.

Wearable EEG Is Moving Toward Early Cognitive-Impairment Screening

Wearable EEG devices are being evaluated for detecting mild cognitive impairment using objective neurological biomarkers. A February 2026 systematic review in npj Digital Medicine assessed 21 studies covering 16 wearable EEG devices and reported classification accuracy ranging from 46% to 95%. The research highlighted multimodal data integration, improved signal processing, standardized protocols, and real-world validation as major development priorities.

Competitive Landscape

Major players operating in the global brain monitoring market include Nonin Medical Inc., Koninklijke Philips NV, Cadwell Laboratories, Elekta AB, Masimo Corporation, Nihon Kohden Corporation, Compumedics, Integra LifeSciences, Medtronic PLC, Natus Medical Incorporated, and Advanced Brain Monitoring Inc., among others.

Recent Developments

In April 2026, NTT DATA launched an AI-enabled brain health monitoring service in Japan that analyzes driving data from GPS-equipped dashcams and generates periodic brain health scores. The service evaluates speed, acceleration, and high-risk driving behaviors to increase awareness of cognitive changes and improve road safety. Japanese taxi operator km Taxi will trial the solution among approximately 700 employees aged 65 and above, supporting health guidance and safer driving practices. (Source: NTT DATA)
In April 2026, Medtronic launched its Adaptive Deep Brain Stimulation system in India for people with Parkinson’s disease. Using FDA-approved BrainSense technology, the system monitors brain signals and automatically adjusts stimulation in real time according to patients’ changing conditions or medication needs. The technology aims to provide more consistent symptom control, reduce treatment-related side effects, extend implanted-device battery life, and improve patients’ daily functioning, outcomes, and overall quality of life. (Source: Medtronic)
In September 2025, Nihon Kohden launched its VitalEEG wireless electroencephalogram (EEG) headset for rapid evaluation of brain-wave information of unconscious patients.
In February 2025, Medtronic and the Medical University of South Carolina (MUSC) announced a five-year value-based healthcare partnership, intended to transform and improve care for patients in South Carolina.
In July 2025, Integra LifeSciences acquired Arkis Bioscience Inc. to expand the product portfolio of Integra’s neurocritical care.